United States Picture Archiving and Communication Systems (PACS) Market is About to Reach $3.3 billion by 2020, Finds New Report

Government initiatives will continue to encourage the digitization of healthcare systems and promote technical advances in imaging informatics. Moreover, the awareness of the importance of digitizing image storage, retrieval and sharing has led to expansion of the use of PACS to other medical specialties such as oncology and endoscopy. This expansion will further result in increased usage of PACS in cardiology imaging, which will in turn drive revenue growth during the forecast period.

An increasing need for upgrades to conventional PACS systems to new, feature-rich PACS that enable interoperability and flexibility in image viewing will drive future growth in the developed world. Developed economies such as the US and Europe will primarily be replacement markets for PACS systems as penetration is already high. However, companies are shifting their focus to developing economies, where penetration is low. A lack of reimbursement and affordability, however, means that countries such as India and China will require low-cost PACS units. There is therefore an urgent need for companies to develop affordable PACS systems that do not compromise on features such as integration with Electronic Medical Records (EMR) and Radiology Information Systems (RIS). This will allow them to sustain revenue growth during the forecast period, as intense competition will continue to drive down the prices of PACS systems.

Government Efforts towards Healthcare IT Implementation and Technical Advances will Continue to Drive Future Growth:

Technical advances in PACS in combination with initiatives from both the public and private sector have contributed to the increasing adoption of PACS by healthcare providers. Rising healthcare cost burdens and demographic changes have forced governments worldwide to improve healthcare delivery services while also reducing costs. This has placed increasing pressure on governments to address financial constraints and improve efficiency and affordability in healthcare. The global population is forecast to reach 9.1 billion by 2050 and the population aged 65 years and above is expected to double by 2050 (United Nations News Centre, 2013). Aging populations will result in an increase in the prevalence of chronic diseases worldwide, which will be accompanied by growing image volumes for diagnosis. These trends have forced governments to initiate efforts in increasing the adoption of PACS to improve hospital productivity and clinical outcomes.

Governments in the developed world have announced several economic and legislative incentives to promote the adoption of healthcare Information Technology (IT) in their countries. The Chinese government has spent close to $500 billion since the launch of its healthcare reforms in 2009, with a significant portion of this investment being made on the adoption of healthcare IT in China (gbtimes, 2014).

Supply-side initiatives to improve PACS systems have spurred technical advances in the recent past. Cloud-based PACS and web-based PACS solutions are some of the examples of advancements that have led to increasing adoption of PACS in recent years. These Software-as-a Service (SaaS) models have expanded the use of PACS in small- and medium-sized hospitals. Other technical advances such as speech recognition capabilities and decision support systems will continue to drive the demand for PACS.

Technical advances have transformed PACS from being a mere storage and viewing tool to being a decision support system that helps in accurate diagnosis of chronic diseases. The ability to integrate EMR and other information systems to PACS has led to companies developing one-stop PACS solutions that can store, retrieve and share images within various hospital departments such as cardiology, oncology and mammography. This is another factor that will help companies to exploit the market potential for PACS over the forecast period.

The US is the Largest Market for Picture Archiving and Communication Systems:

The US market for PACS was valued at $1.7 billion in 2013 and is forecast to reach $3.3 billion by 2020, growing at a CAGR of 8%. It is the largest market for PACS and accounts for 58% of global revenue. The US is followed by Japan, which accounted for 23% of the global market. Europe and Asia-Pacific contributed the remaining shares of the global market. The penetration of radiology PACS is already high in US hospitals, and therefore future growth is expected to be subdued. However, the penetration of PACS in other major applications such as cardiology and oncology is significantly lower. This provides an opportunity for the leading companies in this market to develop feature-rich PACS products that can not only store and retrieve diagnostic images but also help as part of the clinical decision support system. Many hospitals in the US are also considering upgrading their conventional PACS systems with new systems that are web-enabled and support interoperability with different vendors for integration with EMR and other information systems. The Health Information Technology for Economic and Clinical Health (HITECH) Act, with its three staged meaningful adoption mandates and significant financial incentives, will continue to increase the adoption of PACS in the US. Increasing preference for mobile IT applications, SaaS based services and standardization of data archiving will further drive the growth of PACS during the forecast period.

Top Four Companies Account for More than 50% of the Global Market:

In 2013, the top four companies accounted for more than 50% of the global PACS market. The global market is a fragmented one with no company having a dominant position in 2013. GE Healthcare (16.4%), Fujifilm (14.1%) and Philips Healthcare (12.4%) were the leaders in the PACS market in 2013. Agfa Healthcare (10.2%), McKesson (9%), Merge Healthcare (7.1%), Carestream Health (6.5%) and Siemens Healthcare (5.6%) also had significant presence in this market. Fujitsu (3.5%) had a minor presence in the global PACS market. GE Healthcare dominates the global market due to its widespread geographical presence. GE Healthcare is the leader in the North American region and has the second largest presence in terms of revenue in the Asia-Pacific region. GE Healthcare’s presence in the Asia-Pacific region is expected to benefit the company as it stands to gain from the rapidly growing economies of countries such as India and China in the Asia-Pacific region. GE Healthcare has a strong portfolio of PACS systems with specifications catering to imaging centers of all sizes.

Spanning over 68 pages, 33 tables and 33 figure “Picture Archiving and Communication Systems Market to 2020 - Digitization of Healthcare Systems and Evolution of PACS as a Decision Support Tool Drive Growth” report covering the Global Picture Archiving and Communication Systems Market: Definitions; Picture Archiving and Communication Systems: Global Market Characterization; Global Picture Archiving and Communication Systems Market: Country Analysis and Forecasts; Global Picture Archiving and Communication Systems Market: Competitive Landscape; Global Picture Archiving and Communication Systems Market: Product Pipeline Analysis; Global Picture Archiving and Communication Systems Market: Consolidation Landscape. Company covered in this report are: GE Healthcare, Fujifilm Holdings Corporation, Philips Healthcare, Agfa-Gevaert , McKesson Corporation, Carestream Health, Siemens Healthcare, Sectra AB , Cerner Corporation, Merge Healthcare.

Know more about this report at: http://mrr.cm/ZRS

To browse more Medical Devices Reports visit: 

http://www.marketresearchreports.com/medical-devices

Market Snapshot - Aesthetic Lasers and Energy Devices Market 2006 to 2020 - Europe (Germany, France, Italy, UK, Spain), New Report Launched

Market Snapshot: Aesthetic Lasers and Energy Devices Market 2006 to 2020 - Europe (Germany, France, Italy, UK, Spain) report provides quantitative analysis of the three aesthetic lasers and energy devices market segments: minimally invasive body contouring devices, non-invasive body contouring devices and laser resurfacing devices. The analysis includes market size data by revenue and volume over the 2006-2020 period for the following countries: Germany, France, Italy, UK and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts.

Scope

• Information on market size for the three aesthetic lasers and energy devices market segments: minimally invasive body contouring devices, non-invasive body contouring devices and laser resurfacing devices.
• Annualized sales data by revenue for the 2006-2020 period and company share data by revenue for 2013
• Annualized sales data by volume for the 2006-2020 period
• Coverage of key geographies: Germany, France, Italy, UK and Spain

Reasons to buy

• Derive actionable insights from value-volume relationships
• Analyze value-volume relationships and provide direction to marketing and sales strategies
• Develop market-entry and market-expansion strategies
• Identify the key players best positioned to take advantage of opportunities in the European market

Spanning over 55 pages, “Market Snapshot: Aesthetic Lasers and Energy Devices Market 2006 to 2020 - Europe (Germany, France, Italy, UK, Spain)” report covering the Definitions, Aesthetic Lasers and Energy Devices Market, Europe, Revenue, 2006-2020, Aesthetic Lasers and Energy Devices Market, Germany, Revenue and Volume, 2006-2020, Aesthetic Lasers and Energy Devices Market, France, Revenue and Volume, 2006-2020, Aesthetic Lasers and Energy Devices Market, Italy, Revenue and Volume, 2006-2020, Aesthetic Lasers and Energy Devices Market, UK, Revenue and Volume, 2006-2020, Aesthetic Lasers and Energy Devices Market, Spain, Revenue and Volume, 2006-2020, Appendix.

Know more about this report at – http://mrr.cm/ZR5

To browse more Medical Devices Reports visit:  

http://www.marketresearchreports.com/medical-devices

Pancreatic Cancer Treatment Market to Reach $1.63 billion in the US and 5EU by 2017

New Drug Launches Will Drive Rapid Growth in the US and EU Pancreatic Cancer Market from 2012-2017

Publisher estimates that the value of the pancreatic cancer market in the US and 5EU (France, Germany, Italy, Spain, and the UK) in 2012 was $529m. By 2017, the end of the forecast period, research projects pancreatic cancer sales to rise to $1.63 billion in the US and 5EU, at a high Compound Annual Growth Rate (CAGR) of 25.2%. Research expects the proportion of sales from the US to increase to 72%, with market share in the 5EU decreasing to 28% by 2017. The overall rapid increase in the market size across the 6MM is attributed to the launch of Celgene's Abraxane in 2013 in the US and 2014 in Europe, and the incorporation of five pipeline agents into US clinical practice by the end of the forecast period.

Major drivers of the pancreatic cancer market in the US and 5EU during the forecast period include the following:

• The greatest driver of the pancreatic cancer market across the 6MM will be the strong and rapid adoption of premium-priced Abraxane in place of generic chemotherapy regimens, such as FOLFIRINOX (5-flourouracil [5-FU]/leucovorin/irinotecan/oxaliplatin) and gemcitabine monotherapy. GlobalData forecasts particularly strong growth in the US, the largest market for pancreatic cancer therapeutics, and the market where Abraxane is priced the highest.
• Of the five new pipeline agents that will be launched during the forecast period, NewLink Genetics Corporation's algenpantucel-L is expected to garner the highest sales, and is expected to launch in both the resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck's TH-302, and Merrimack Pharmaceuticals' MM-398.
• The incidence of pancreatic cancer is increasing across the 6MM, resulting in further treatment opportunities for premium-priced therapeutics.

Reasons to Buy

• Overview of pancreatic cancer, including epidemiology, etiology, pathophysiology, symptoms, prognosis, and clinical staging.
• Topline pancreatic cancer therapeutics market revenue from 2012-2017. Annual cost of therapy, and major marketed and pipeline drug sales in this forecast period are included.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the pancreatic cancer therapeutics market.
• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available.
• Analysis of the current and future market competition in the 6MM pancreatic cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Spanning over 179 pages, “OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017” report covering the Introduction, Disease Overview, Epidemiology, Current Treatment Options, Unmet Needs Assessment and Opportunity Analysis, Research and Development Strategies, Pipeline Assessment, Pipeline Valuation Analysis, Appendix.

Know more about this report at – http://mrr.cm/ZU2

To browse more Diagnostics Reports visit: 

 http://www.marketresearchreports.com/diagnostics 

Neurovascular Interventions Market is Lead by Japan and European Countries, Finds New Report

Combined, the US, five European Union countries (5EU) (France, Germany, Italy, Spain, and UK), and Japan, account for approximately 80% of the neurointerventional market for cerebrovascular applications. The US is forecast to have the largest market share in the market, followed by Japan, and then collectively, the 5EU. Innovative technologies such as flow diverters and stent retrievers have not received regulatory approval and been launched in the Japanese market. Stent retrievers and flow diverters are expected to enter Japan beginning in 2015.

Physicians believe flow diverters are innovative technologies that will be adopted for challenging intracranial aneurysms in the future. However, they question widespread adoption given the complications/challenges associated with flow diversion devices.

Key Drivers in the Global Neurovascular Interventions Market

The key drivers for this market during the forecast period are:

• The rising prevalence of cerebrovascular disease and its associated risk factors in the major markets.
• The need for effective therapies that reduce the risk of hemorrhagic and stroke complications, and ensure long-term, reliable outcomes.
• The increased use of remodeling techniques such as stent-assisted and balloon-assisted coiling, and the adoption of flow diverters for the treatment of challenging/complex aneurysms (wide-neck, large, and giant aneurysms).                    
• The cost savings for healthcare payers resulting from the reduced need for repeat procedures.
• The increase in patients' disposable income and government insurance coverage in the emerging markets, such as China and India.
• The approval and launch of the next-generation of innovative embolization, revascularization, and mechanical thrombectomy devices in the US and Japan.

Reasons to Buy

• Overview of cerebrovascular disease, including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities
• Annualized total neurovascular interventions market revenue by device segment, annual cost of disease and neurointerventional devices adoption pattern and procedure data from 2011-2013 and forecast to 2020
• Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in each region covered in the report, and implications of the neurovascular interventions market
• Pipeline analysis: comprehensive data split across different stages of development, emerging trends and device designs in development
• Analysis of the current and future market competition in the global neurovascular interventions market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Spanning over 432 pages, “MediPoint: Neurovascular Interventions - Global Analysis and Market Forecasts” report covering the Introduction, Clinical Outcomes, Industry Overview, Unmet Needs, Market Opportunity Analysis, Market Drivers and Barriers, Competitive Assessment, Pipeline Assessment, Clinical Trial Analysis, Current and Future Players, Market Outlooks, Appendix. The report covered few companies are - BALT Extrusion, Covidien, Johnson & Johnson, Penumbra, Stryker Corporation, Terumo Corporation, Abbott Vascular, Boston Scientific Corporation, Cook Medical, Gore Medical, Medtronic

Know more about this report at – http://mrr.cm/ZXo

To browse more Pharma and Healthcare Reports visit:  

http://www.marketresearchreports.com/pharma-healthcare  

U.S. Market for Soft Tissue Reinforcement and Regeneration 2015, New Report Launched

The U.S. market for soft tissue reinforcement and regeneration includes medical graft devices that are designed to reinforce and regenerate soft tissues. Soft tissues are defined as aggregations of similarly specialized cells which collectively function to connect, support or surround other structures and organs of the body. These tissues include tendons, ligaments, fascia, skin, fibrous tissues, fat, synovial membranes, muscles, nerves and blood vessels. Collagen, the most abundant protein in mammals, is one of the characteristic elements inside the extracellular matrix of soft tissue and, as such, plays a critical role in soft tissue repair. Since soft tissue essentially makes up the majority of a person and there are countless medical conditions associated with soft tissue problems, a select group of large markets related to soft tissue repair will be covered in this report, including breast reconstruction, hernia repair, dural repair, vaginal slings, skin repair, sports medicine and tendon reinforcement, and dental soft tissue regeneration.

There are three primary classes of soft tissue repair devices; allografts, xenografts, and alloplasts.

The U.S. soft tissue reinforcement and regeneration market consists of specialized grafting devices utilized for the surgical treatment of a broad range of indications. While synthetic alloplast products have been traditionally used, newer biologic products have been gaining traction in this market. These new products offer superior regenerative results by expediting the healing process and reducing the likelihood of further post-operative complications.

Biologic products have a significantly higher cost, but in most cases, the added benefits they offer outweigh their premium prices. The increasing unit sales of these specialized biologic products combined with their substantially higher ASP will fuel strong growth in the overall market.

The breast reconstruction market will more than double in value over the forecast period. Exceptionally strong double-digit growth will be driven by increases in unit sales volumes. The breast reconstruction market will more than double in value over the forecast period. Exceptionally strong double-digit growth will be driven by increases in unit sales volumes.

The incidence of breast cancer in younger women has been increasing in the United States; this population is more likely to opt for both mastectomy and breast reconstruction. The vast majority of breast reconstructions were tissue expander/implant–based (TEI) reconstructions. The remaining procedures were performed with autologous tissue, using techniques such as latissimus dorsi myocutaneous (LDM) flap, deep inferior epigastric perforators (DIEP) flap and transverse rectus abdominis myocutaneous (TRAM) flap.

U.S., 2011 – 2021

In the last few decades, there has been an ongoing trend in the U.S. for women to undergo a prophylactic double mastectomy for preventative measures, even if breast cancer was only diagnosed in one breast. If the patient then decides to undergo breast reconstruction, both breasts must be completely rebuilt. This has caused the rate of bilateral reconstructions to skyrocket and has dramatically impacted the growth of the breast reconstruction market, as one product is usually used for each breast during a reconstructive procedure.

• Analyzes trends between biologic products (allografts and xenografts) and synthetic products
• Covers a broad range of soft tissue related ailments and the graft products used to treat them
• Descriptive and qualitative information for the market drivers and limiters for each chapter
• Section on mergers and acquisitions for 2013 and 2014
• Full competitive analysis of leading competitors
• Discusses the rate of bilateral reconstructions, which is unique in the U.S. compared to other countries
• Discusses differences in growth and price between allografts, xenografts, and alloplasts used for breast reconstructions
• Added sub segments to alloplast segment which include a discussion of difference between growth and price between newer composite alloplasts and the traditional uncoated alloplasts
• Discusses differences in growth and price between biologics and synthetics used for stress urinary incontinence
• Recent changes in reimbursement have and will affect this market
• Compares trends in products used for Achillies tendon reinforcement and rotator cuff reinforcement
• Separated and removed barrier membrane products in order to focus solely on devices that facilitate soft tissue regeneration, resulting in dramatic changes in competitive landscape and amount of growth

Spanning over 225 pages, “U.S. Market for Soft Tissue Reinforcement and Regeneration 2015” report covering the Executive Summary, Research Methodology, U.S. Soft Tissue Reinforcement And Regeneration Market, Procedures, Breast Reconstruction Market, Hernia Repair Market, Hernia Repair Market, Dural Repair Market, Vaginal Sling Market, Skin Repair Market, Sports Medicine And Tendon Reinforcement Market, Dental Soft Tissue Regeneration Market. The report covered few companies are - LifeCell, Organogenesis, C. R. Bard, Ethicon, Covidien, Wright Medical, American Medical Systems, Boston Scientific, Integra LifeSciences, Smith & Nephew, MiMedx, Coloplast

Know more about this report at – http://mrr.cm/ZaB

To browse more Pharma and Healthcare Reports visit:  

http://www.marketresearchreports.com/pharma-healthcare  

European Markets for Dental Materials 2014, New Report Launched

The dental materials market also commonly referred to as ‘dental consumables’ is comprised of a variety of segments including dental cements, impression materials, direct restorative materials (specifically filling materials), bonding agents, core build-up materials and dental anesthesia. This market constitutes one of the largest in the dental industry and exhibits high potential for further growth.

Competitor Analysis

• Identified Strategic Opportunities
• Market Overview by Segment
• Procedure Numbers
• Unit Sales by Material, Delivery, Curing Method and Application
• Trend Analysis by Segment
• Market Drivers & Limiters
• Mergers & Acquisitions
• Customer Feedback & Market Monitoring

This market is one of the largest in the dental industry and exhibits high potential for further growth. Demand is set to increase for the majority of the segments within this market. The dental materials industry demonstrates continuous technological developments that facilitate workflow and improve patient comfort. The economic downturn impacted the dental restorative markets and resulted in fewer patients visiting the dentist between the years of 2008 and 2011; however, this market is starting to pick back up. Limiting growth in the majority of these segments is the greater emphasis on preventive measures in order to avoid restorative procedures. Also threatening dental material segments is the growth of digitized dentistry.

The segment exhibiting the fastest growth is the direct restorative market. This phenomenon stems from the surging growth demonstrated within the subsegment for composite material at the expense of that of amalgam. The second highest growth rate is found in the bonding agent market. The general aesthetic trend towards resin-based direct and indirect restoratives has led to a growing demand for bonding agents.

Scope of Report:  This report pertains to a forecast period of 10 years (2010 – 2020):

• Minimal information is available on the dental materials market as not very much research has been conducted effectively
• Complex market to understand especially in regards to market volumes
• Sheds light on a market that is ever changing in terms of technological advancements
• Reveals interesting market trends that have been driving and limiting the market
• Exposes potential threats and opportunities in the market
• Illustrates growth trends over a 10 year period
• Highlights key competitors in the market and relevant competitive advantages
• Reveals differences in growth patterns and price variations between the two Cements  segments
• Discusses innovative delivery methods of dental cements and illustrates unit sales dependent on the delivery type
• Compares and contrasts the various segments based on pricing, delivery method and popularity throughout various regions in Europe
• Segments the market into preliminary and precision impression materials, namely based on material type: alginates, silicones and polyether materials
• Illustrates the ever-changing growth trends present in the various etching markets
• Points to regional differences corresponding to dominant etchant types
• Segments the market into the two dominant material types (composites and glass ionomers) while accounting for a residual ‘other’ category
• Discusses the various local injection types and their prevalence across Europe, especially described in depth in the unit analysis
• Discusses factors contributing to procedure number sizes across various European regions
• Illustrates growth trends of various procedures

Spanning over 399 pages, “European Markets for Dental Materials 2014” report covering the Executive Summary, Research Methodology, European Market For Dental Materials, Dental Material Procedures, Country Profiles, Dental Cement Market, Dental Impression Material Market, Direct Restorative Material Market, Dental Bonding Agent Market, Dental Core Build-Up Material Market, Dental Anesthetic Market. The report covered 12 companies - 3M ESPE, DENTSPLY, GC Europe, Heraeus Kulzer, Ivoclar Vivadent, Kettenbach, Kuraray, KerrHawe, Septodont, VOCO, Coltene Whaledent, DMG

Know more about this report at – http://mrr.cm/ZaX

To browse more Medical Devices Reports visit:  

http://www.marketresearchreports.com/medical-devices

The U.S. Wound Management Market is Expected to Reach $10billion by 2020; Reveals New Report

The wound and tissue management market includes wound closure devices; static and dynamic compression therapy; moist, antimicrobial, interactive wound dressings; non-adherent contact layers; hemostats; tissue sealants; anti-adhesion; and negative pressure wound therapy.  This report details the expected growth rates, average selling prices (ASP) and market values of these interlinked segments.

The U.S. Wound Management Market growth will be driven by the introduction of new products that will be easier to use. However, this will be hindered by changes to reimbursement, specific to the U.S. interactive dressings market. The interactive dressings market is further segmented into collagen dressings and skin substitutes. The interactive dressings market experienced double digit growth in 2013 and the emergence of many new players in the market.

The U.S market for wound and tissue management was driven by the introduction of newly FDA-approved products, and by demand due to the aging population, and increasing rates of both obesity and diabetes. The advanced wound dressings segment exhibited the highest growth in 2013. This growth will be due to the rising popularity of foam dressings, antimicrobial dressings and the influx of competitors and innovative products in the interactive dressing market. The reimbursement changes in 2014 will potentially have a negative impact on the growth of the interactive dressing market.

The range of products in the wound management industry is as diverse as the conditions they are meant to treat. The use of traditional dressings has stood the test of time and these will remain important products. This market will exhibit slow but healthy growth over the forecast period due to its sheer size. However, advanced dressings are the way of the future and there is still a large untapped potential market. Advanced dressings decrease the frequency a dressing must be changed and due to the commoditization of these products, the price gap between the two, traditional and advanced, is decreasing. Over the forecast period, companies which are able to modify and enhance their advanced dressing portfolio will be able to grow with the shift in product usage.

Growth in the negative pressure wound therapy market was significantly affected by the competitive bidding process. This market is expected to rebound and post growth in the high single-digits over the forecast period. Growth will be supplemented by improved reimbursement rates for single use negative pressure wound therapy pumps and an increase in the number of competitors.

Image: Collagen Dressing Market, U.S. 2010 - 2020 (See attached Chart image) (Source: i-data research)

With the baby boomers aging, the total number of people over the age of 65 is drastically increasing within the United States. With an aging population comes the requirement for more surgical procedures, all risking the possibility of circulatory issues. As a result, a greater number of devices used in surgery, such as wound closure devices, hemostats and tissue sealants, will be purchased. Therefore, sales of products that enhance circulation to treat lymphedema and chronic wounds are expected to increase to meet the growing demand of this population.

The wound and tissue management market is consistently changing through new reimbursement rates, FDA approval and product innovation. A company which was once a dominant player in a market can lose market share quickly due to a number of different factors. KCI continues to lead the negative pressure wound therapy market but their revenue was significantly affected by the competitive bidding process, which allowed Smith & Nephew to increase their market share. Shire, a once dominant player in the interactive dressing market, saw their revenue significantly decrease year-over-year due to their highlight product not receiving FDA approval for additional usage.

Report Highlights:

• Introduction of newly FDA-approved products
• Reimbursement change effects on the market
• Mainstay products in the wound closure market, such as sutures
• Improved advanced wound closure devices, such as cyanoacrylate-based tissue adhesives
• DME competitive bidding proccess effects on various markets

Spanning over 353 pages, “U.S. Market for Wound and Tissue Management 2014” report covering the Executive Summary, Research Methodology, U.S. Wound And Tissue Management Market Overview, Wound Closure Market, Static Compression Therapy Market, Dynamic Compression Therapy Market, Advanced Dressing Market Overview, Moist Dressing Market, Antimicrobial Dressing Market, Interactive Dressing Market, Non-Adherent Contact Layer Market, Traditional Wound Dressing Market, Hemostat Market, Tissue Sealant Market, Anti-Adhesion Market, Negative Pressure Wound Therapy Market. The report covered few companies are - Ethicon, Covidien, KCI, Medline, Smith & Nephew, 3M, Organogenesis, Baxter, Pfizer, Mölnlycke, ConvaTec, BSN-JOBST.

Know more about this report at – http://mrr.cm/Za2

To browse more Pharma and Healthcare Reports visit:  

http://www.marketresearchreports.com/pharma-healthcare